Compare ANAB & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANAB | RAPP |
|---|---|---|
| Founded | 2005 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2015 | 2024 |
| Metric | ANAB | RAPP |
|---|---|---|
| Price | $64.67 | $30.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $68.10 | $47.00 |
| AVG Volume (30 Days) | ★ 442.0K | 302.6K |
| Earning Date | 05-25-2026 | 06-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $234,603,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $15.32 | $7.73 |
| 52 Week High | $63.47 | $42.27 |
| Indicator | ANAB | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 68.28 | 57.84 |
| Support Level | $43.67 | $25.40 |
| Resistance Level | N/A | $42.27 |
| Average True Range (ATR) | 3.61 | 2.10 |
| MACD | 0.67 | 0.09 |
| Stochastic Oscillator | 88.63 | 78.03 |
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.